Injectafer Rejected For First-Line Use; Promising For Second-Line, Panel Says
Executive Summary
Luitpold's Injectafer should be reserved for second-line use for treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, FDA's Drug Safety and Risk Management Advisory Committee recommended Feb. 1
You may also be interested in...
Drug Approval News, In Brief
FDA’s recent actions include approval for Horizon’s Rayos delayed-release prednisone and “complete response” letters for two other drugs – Otsuka/Lundbeck’s depot injection of the atypical antipsychotic aripiprazole and Luitpold’s iron deficiency anemia treatment Injectafer.
Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.